| Barrett Wesley Compton, DO | |
|
5016 S Us Highway 75, Attn: Residency Program, Denison, TX 75020-4584 | |
| (817) 480-4840 | |
| (903) 416-6195 |
| Full Name | Barrett Wesley Compton |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 9 Years |
| Location | 5016 S Us Highway 75, Denison, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013391598 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | BP10054760 594750 (Texas) | Secondary |
| 207Q00000X | Family Medicine | R2836 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Methodist Mckinney Hospital | Mckinney, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Texas Emergency Physicians Pllc | 1759303613 | 19 |
| Legacy Urgent Care Pa | 3072679828 | 119 |
News Archive
Researchers at the Institute of Molecular Biology in Mainz, Germany, have made a breakthrough in understanding the origin of the aging process. They have identified that genes belonging to a process called autophagy - one of the cells most critical survival processes - promote health and fitness in young worms but drive the process of aging later in life.
Ischemia is a serious medical condition in which the flow of blood and delivery of oxygen to tissues is restricted, thus resulting in pain, weakness, and more seriously, tissue and organ damage. Ischemia in muscle tissue, most commonly as a result of atherosclerosis, leads to life-threatening diseases like coronary artery disease and stroke, but also to chronic peripheral artery disease (PAD).
Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.
Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.
› Verified 6 days ago
| Entity Name | Western Texas Emergency Physicians Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184674020 PECOS PAC ID: 1759303613 Enrollment ID: O20051220000946 |
News Archive
Researchers at the Institute of Molecular Biology in Mainz, Germany, have made a breakthrough in understanding the origin of the aging process. They have identified that genes belonging to a process called autophagy - one of the cells most critical survival processes - promote health and fitness in young worms but drive the process of aging later in life.
Ischemia is a serious medical condition in which the flow of blood and delivery of oxygen to tissues is restricted, thus resulting in pain, weakness, and more seriously, tissue and organ damage. Ischemia in muscle tissue, most commonly as a result of atherosclerosis, leads to life-threatening diseases like coronary artery disease and stroke, but also to chronic peripheral artery disease (PAD).
Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.
Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.
› Verified 6 days ago
| Entity Name | Legacy Urgent Care Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568622272 PECOS PAC ID: 3072679828 Enrollment ID: O20090304000140 |
News Archive
Researchers at the Institute of Molecular Biology in Mainz, Germany, have made a breakthrough in understanding the origin of the aging process. They have identified that genes belonging to a process called autophagy - one of the cells most critical survival processes - promote health and fitness in young worms but drive the process of aging later in life.
Ischemia is a serious medical condition in which the flow of blood and delivery of oxygen to tissues is restricted, thus resulting in pain, weakness, and more seriously, tissue and organ damage. Ischemia in muscle tissue, most commonly as a result of atherosclerosis, leads to life-threatening diseases like coronary artery disease and stroke, but also to chronic peripheral artery disease (PAD).
Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.
Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Barrett Wesley Compton, DO 5016 S Us Highway 75, Attn: Residency Program, Denison, TX 75020-4584 Ph: (817) 480-4840 | Barrett Wesley Compton, DO 5016 S Us Highway 75, Attn: Residency Program, Denison, TX 75020-4584 Ph: (817) 480-4840 |
News Archive
Researchers at the Institute of Molecular Biology in Mainz, Germany, have made a breakthrough in understanding the origin of the aging process. They have identified that genes belonging to a process called autophagy - one of the cells most critical survival processes - promote health and fitness in young worms but drive the process of aging later in life.
Ischemia is a serious medical condition in which the flow of blood and delivery of oxygen to tissues is restricted, thus resulting in pain, weakness, and more seriously, tissue and organ damage. Ischemia in muscle tissue, most commonly as a result of atherosclerosis, leads to life-threatening diseases like coronary artery disease and stroke, but also to chronic peripheral artery disease (PAD).
Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.
Janssen Research & Development, LLC today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the use of the investigational drug bedaquiline (TMC207) as an oral treatment, to be used as part of combination therapy for pulmonary, multi-drug resistant tuberculosis (MDR-TB) in adults.
› Verified 6 days ago
Diego F. Restrepo, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5012 S Us Highway 75, Suite 300, Denison, TX 75020 Phone: 903-416-6025 Fax: 903-416-6138 | |
John B Sissney, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5012 S Us Highway 75 Ste 300, Denison, TX 75020 Phone: 903-416-6025 Fax: 903-416-6138 | |
Dr. Sarah Branam, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5012 S Us Highway 75 Ste 225, Denison, TX 75020 Phone: 903-416-6025 Fax: 903-416-6195 | |
Angela C Latham, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5012 S Us Highway 75, Suite 225, Denison, TX 75020 Phone: 903-416-6025 Fax: 903-416-6195 | |
Jimmy L Tarpley, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5012 S Us Highway 75 Ste 225, Denison, TX 75020 Phone: 903-416-6025 Fax: 903-416-6195 | |
Dr. Nickolas Baker, D.O Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5016 S Us Highway 75, Denison, TX 75020 Phone: 903-416-4002 Fax: 903-416-4129 |